
==== Front
BMC Infect Dis
BMC Infect Dis
BMC Infectious Diseases
1471-2334
BioMed Central London

39300365
9783
10.1186/s12879-024-09783-2
Research
Comparison of characteristics of children hospitalized for respiratory syncytial virus infection during the pre- and post-COVID-19 eras: a multicenter retrospective study
Liu Hai-Feng 1
Wang Ya-Yu 2
Zhang Xue-Zu 3
Li He-Yun 4
Xiang Mei 5
Lu Rui 6
Liu Cong-Yun 7
Li Wang 8
Feng Quan-Li 1
Guo Yun-Jie 1
Huang Rong-Wei 1
Fu Hong-Min fuhongmin@kmmu.edu.cn

1
1 grid.285847.4 0000 0000 9588 0960 Department of Pulmonary and Critical Care Medicine, Yunnan Key Laboratory of Children’s Major Disease Research, Yunnan Medical Center for Pediatric Diseases, Kunming Children’s Hospital, Kunming Medical University, No. 28, Shulin Street, Xishan District, Kunming, 650034 China
2 https://ror.org/02y7rck89 grid.440682.c 0000 0001 1866 919X Department of Pediatrics, The People’s Hospital of Dali, The Third Affiliated Hospital of Dali University, Dali, 671000 China
3 grid.411634.5 0000 0004 0632 4559 Department of Pediatrics, The People’s Hospital of Lincang, Lincang, 677000 China
4 grid.285847.4 0000 0000 9588 0960 Department of Pediatrics, The First People’s Hospital of Zhaotong, Zhaotong Hospital, Affiliated to Kunming Medical University, Zhaotong, 657000 China
5 https://ror.org/01gkbq247 grid.511424.7 Department of Pediatrics, The People’s Hospital of Honghe, Mengzi, 651400 China
6 Department of Pediatrics, The People’s Hospital of Wenshan Zhuang & Miao Autonomous Prefecture, Wenshan, 663000 China
7 Department of Pediatrics, The People’s Hospital of Baoshan, Baoshan, 678000 China
8 Department of Pediatrics, The People’s Hospital of Guandu District, The Fifth People’s Hospital of Kunming, Kunming, 650200 China
19 9 2024
19 9 2024
2024
24 100913 3 2024
21 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Respiratory syncytial virus (RSV), a leading cause of lower respiratory tract infection (LRTI) among children, has resurged in the form of endemic or even pandemic in many countries and areas after the easing of COVID-19 containment measures. This study aimed to investigate the differences in epidemiological and clinical characteristics of children hospitalized for RSV infection during pre- and post-COVID-19 eras in Yunnan, China.

Methods

A total of 2553 pediatric RSV inpatients from eight hospitals in Yunnan were retrospectively enrolled in this study, including 1451 patients admitted in 2018–2019 (pre-COVID-19 group) and 1102 patients admitted in 2023 (post-COVID-19 group). According to the presence or absence of severe LRTI (SLRTI), patients in the pre- and post-COVID-19 groups were further divided into the respective severe or non-severe subgroups, thus analyzing the risk factors for RSV-associated SLRTI in the two eras. Demographic, epidemiological, clinical, and laboratory data of the patients were collected for the final analysis.

Results

A shift in the seasonal pattern of RSV activity was observed between the pre-and post-COVID-19 groups. The peak period of RSV hospitalizations in the pre-COVID-19 group was during January–April and October–December in both 2018 and 2019, whereas that in the post-COVID-19 group was from April to September in 2023. Older age, more frequent clinical manifestations (fever, acute otitis media, seizures), and elevated laboratory indicators [neutrophil-to-lymphocyte ratio (NLR), c-reactive protein (CRP), interleukin 6 (IL-6), co-infection rate] were identified in the post-COVID-19 group than those in the pre-COVID-19 group (all P < 0.05). Furthermore, compared to the pre-COVID-19 group, the post-COVID-19 group displayed higher rates of SLRTI and mechanical ventilation, with a longer length of hospital stay (all P < 0.05). Age, low birthweight, preterm birth, personal history of atopy, underlying condition, NLR, IL-6 were the shared independent risk factors for RSV-related SLRTI in both pre- and post-COVID-19 groups, whereas seizures and co-infection were independently associated with SLRTI only in the post-COVID-19 group.

Conclusions

An off-season RSV endemic was observed in Yunnan during the post-COVID-19 era, with changed clinical features and increased severity. Age, low birthweight, preterm birth, personal history of atopy, underlying condition, NLR, IL-6, seizures, and co-infection were the risk factors for RSV-related SLRTI in the post-COVID-19 era.

Keywords

Respiratory syncytial virus
Children
Post-COVID-19 era
Severe lower respiratory tract infection
Risk factors
http://dx.doi.org/10.13039/501100019413 Yunnan Provincial Department of Education Science Research Fund Project 2023Y0790 http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 81960021 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Respiratory syncytial virus (RSV) represents a leading cause of lower respiratory tract infection (LRTI) in young children across the globe [1]. It was estimated that there were approximately 33.1 million episodes of RSV-related LRTI per year, resulting in 3.2 million hospital admissions and 59,600 in-hospital deaths among children aged below 5 years [2]. Of which, severe LRTI (SLRTI) has long been identified as the most dominant factor responsible for pediatric RSV-associated deaths, especially in developing countries [3, 4]. In the past, RSV activity was highly predictable due to marked seasonality in transmission, with peak seasons from October to the following April in the Northern Hemisphere and from April to September in the Southern Hemisphere [5]. However, this stable seasonal pattern of RSV spread was broken by the COVID-19 pandemic, which had posed catastrophic consequences to public health worldwide [6].

In response to the COVID-19 pandemic, most countries around the world implemented a series of rigorous non-pharmaceutical interventions (NPIs). Substantial evidence suggested that while the strict NPIs were effective in controlling COVID-19 pandemic, they also limited the seasonal circulation of RSV, with a significant decline in detection rates reaching up to 98% during the pandemic [7, 8]. However, as widely known, because of the lack of licensed RSV vaccines and the gradual decrease of maternal RSV neutralizing antibodies with increasing age, seasonal exposure to RSV has served as the primary way for children to acquire immune protection against RSV infection [9, 10]. Logically, the reduced seasonal exposure to RSV during the COVID-19 pandemic would enhance susceptibility to RSV in children, thereby increasing the severity of RSV infection. Indeed, with the gradual lifting of NPIs in the post-COVID-19 era, numerous countries, such as Australia, New Zealand, Italy, Japan, and China, have reported out-of-season RSV outbreaks, with increased proportions of RSV hospitalizations and intensive care unit (ICU) admissions [7, 11–14]. Given that COVID-19 pandemic and its related NPIs have affected the seasonal pattern, natural course, and severity of RSV infection in children, studies regarding RSV infection in post-COVID-19 era are urgently needed to further elucidate its epidemiological and clinical characteristics.

In the present study, we retrospectively collected the data on pediatric RSV inpatients at multiple hospitals in Yunnan, China, in 2018–2019 and 2023. A detailed analysis of epidemiology and clinical characteristics of these patients during the pre- and post-COVID-19 eras was performed to evaluate the seasonal and clinical evolution of RSV. In addition, we also compared the risk factors of RSV-associated SLRTI between the two eras, aiming to facilitate the early recognition of severe cases and reducing mortality in such patients during the post-COVID-19 era.

Methods

Study design and population

This multicenter retrospective study was conducted at eight public tertiary hospitals in Yunnan, China, enrolling children (≤ 14 years) hospitalized for RSV infection in 2019 and 2023. Patients admitted during January 2018–December 2019 and January–December 2023 were divided into the pre- and post-COVID-19 groups, retrospectively. Besides, to compare risk factors for RSV-associated SLRTI between the two eras, patients in pre- and post-COVID-19 groups were further classified into the respective severe and non-severe subgroups according to the presence or absence of SLRTI (Fig. 1).

Fig. 1 Flowchart of the overall study design. RSV, respiratory syncytial virus; SLRTI, severe lower respiratory tract infection

SLRTI was defined as pneumonia or bronchiolitis accompanied by at least one of following conditions [15–17]: (1) a reduction in feeding amount to less than half of the normal, dehydration or refusal to feed; (2) disturbed consciousness; (3) manifestations of hypoxemia, including cyanosis, age-specific tachypnea (≥ 60 breaths/min for children under 2 months; ≥50 breaths/min for children aged 2 months to 1 year; ≥40 breaths/min for children aged > 1 to 5 years; ≥30 breaths/min for children older than 5 years), three concave signs, nasal flaring, grunting, intermittent apnea, or oxygen saturation < 88%; (4) persistent high fever for more than 5 days; (5) pulmonary imaging suggesting ≥ 2/3 unilateral lung infiltration, multilobar pulmonary infiltration, pleural effusion, pneumothorax, atelectasis, pulmonary necrosis, or pulmonary abscess; (6) extrapulmonary complications.

Ethical approval for this study was granted by the Ethics Committees of Kunming Children’s Hospital Affiliated to Kunming Medical University (approval number: 2023-05-012-K01), who also waived the written informed consent due to the retrospective design of the study.

Data extraction and definition

Data obtained from electronic medical records included demographic information (age, gender), clinical characteristics [low birthweight, preterm birth, personal and family histories of atopy, non-exclusively breastfeeding (non-EBF), underlying condition, duration of symptoms prior to admission, fever, fever peak, cough, rhinorrhea, nasal congestion, wheezing, acute otitis media, seizures, poor appetite, diarrhea, vomiting], laboratory indicators [oxygen saturation, leucocyte count, neutrophil-to-lymphocyte ratio (NLR), CD4+/CD8+ T cell ratio, erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), procalcitonin (PCT), interleukin 6 (IL-6), alanine transaminase (ALT), aspartate transaminase (AST), lactate dehydrogenase (LDH), creatinine (Cr), urea, creatine kinase myocardial band (CK-MB), co-infection], and outcome measures [SLRTI, mechanical ventilation, ICU admission, length of hospital stay (LOS)].

In the above-mentioned data, low birthweight was defined as a birth weight of less than 2500 g; preterm birth was defined as gestational age < 37 weeks; underlying diseases included congenital heart diseases, bronchopulmonary dysplasia, pectus excavatum, malignant tumors, immunodeficiency, or severe malnutrition; non-EBF was defined as that the feeding practice within 6 months after birth was formula feeding or mixed feeding. In addition, all patients in this study had received the molecular detection of multiple respiratory pathogens, including RSV, influenza A virus (IAV), influenza B virus (IBV), human parainfluenza virus (HPIV), human adenovirus (HAdV), human rhinovirus (HRV), human metapneumovirus (HMPV), SARS-COV-2 (only in the post-COVID-19 era), mycoplasma pneumoniae (M. pneumoniae), chlamydophila pneumoniae, and legionella pneumophila. Co-infection referred to detection of another pathogen concurrent to RSV diagnosis. All data were cross-checked by two trained Ph.D. students to ensure accuracy.

Statistical analysis

Categorical variables were expressed as frequencies (n) and percentages (%) and compared using Pearson’s chi-square or Fisher’s exact test, while continuous variables with non-normal distributions tested by the Shapiro-Wilk test were summarized as medians with interquartile range (IQR) and then compared using Mann-Whitney U test. Multivariate logistic regression analysis was performed to identify the independent risk factors for SLRTI among pediatric RSV inpatients. All statistical analyses were carried out using R 3.5.1 (R Foundation, Vienna, Austria) with a significance level set at a two- tailed P value < 0.05.

Results

General characteristics of patients

During the entire study period, a total of 2553 pediatric RSV inpatients were included in this study. Among which, 1451 cases (658 cases in 2018 and 793 cases in 2019) were enrolled in the pre-COVID-19 group with a median age of 5.5 (2.1, 11.2) months and a male proportion of 59.5% (864/1451), while 1102 cases were enrolled in the post-COVID-19 group with a median age of 15.1 (10.5, 21.6) months and a male proportion of 57.0% (628/1102). Patients in the post-COVID-19 group were significantly older than those in the pre-COVID-19 group (P < 0.001) (Table 1).

Table 1 General characteristics of patients in the pre- and post-COVID-19 groups

Characteristics	Total
(n = 2553)	Post-COVID-19 group (n = 1102)	Pre-COVID-19 group (n = 1451)	P value	
Age, months, median (IQR)	7.4 (3.3, 13.1)	15.1 (10.5, 21.6)	5.5 (2.1, 11.2)	< 0.001	
Male, n (%)	1492 (58.4)	628 (57.0)	864 (59.5)	0.194	
Low birthweight, n (%)	330 (12.9)	155 (14.1)	175 (12.1)	0.135	
Preterm birth, n (%)	336 (13.2)	136 (12.3)	200 (13.8)	0.286	
Personal history of atopy, n (%)	554 (21.7)	249 (22.6)	305 (21.0)	0.339	
Family history of atopy, n (%)	362 (14.2)	168 (15.2)	194 (13.4)	0.179	
Non-EBF, n (%)	1157 (45.3)	505 (45.8)	652 (44.9)	0.654	
Underlying condition, n (%)	361 (14.1)	163 (14.8)	198 (13.6)	0.411	
Duration of symptoms prior to admission, days, median (IQR)	1.0 (1.0, 2.0)	1.0 (1.0, 1.0)	1.0 (1.0, 2.0)	0.219	
IQR, interquartile ranges; Non-EBF, non-exclusively breastfeeding

Epidemiological characteristics of patients

In terms of temporal distribution of admissions (Fig. 2), the post-COVID-19 group showed that the number of RSV hospitalizations began to increase rapidly in April and culminate in August, followed by a sharp decline in October, indicating a peak period of hospitalization in April–September 2023, with the monthly hospitalization counts successively being 98 (8.9%) in April, 131 (11.9%) in May, 172 (15.6%) in June, 187 (17.0%) in July, 192 (17.4%) in August, and 117 (10.6%) in September.

Fig. 2 The temporal distribution of admissions in the pre- and post-COVID-19 groups

In contrast, the period from May to September was an relative trough for RSV hospitalizations in the pre-COVID-19 group, which showed a peak period during January–April and October–December in both 2018 and 2019.

Clinical and laboratory characteristics of patients

There were significant differences regarding clinical and laboratory characteristics between the pre- and post-COVID-19 groups (Table 2). Specifically, despite a deceased proportion of wheezing, more frequent clinical manifestations (fever, acute otitis media, seizures) and significantly elevated laboratory indicators (leukocyte count, NLR, CRP, IL-6, co-infection rate) were found in the post-COVID-19 group than the pre-COVID-19 group (all P < 0.05). More notably, the proportion of patients developing SLRTI was 21.7% (239/1102) in the post-COVID-19 group, with a mechanical ventilation rate of 7.8% (86/1102) and a median LOS of 6.0 (4.0, 8.0) days, all of which were greater than those identified in the pre-COVID-19 group [16.8% (244/1451), 4.8% (70/1451), 5.0 (4.0, 7.0) days, respectively; all P < 0.05] (Table 3).

Table 2 Clinical and laboratory characteristics of patients in the pre- and post-COVID-19 groups

Characteristics	Total
(n = 2553)	Post-COVID-19 group (n = 1102)	Pre-COVID-19 group (n = 1451)	P value	
Clinical symptoms	
   Fever, n (%)	1284 (50.3)	582 (52.8)	702 (48.4)	0.027	
   Fever peak, °C, median (IQR)	37.7 (37.2, 38.2)	37.8 (37.2, 38.4)	37.7 (37.2, 38.1)	0.118	
   Cough, n (%)	2276 (89.2)	993 (90.1)	1283 (88.4)	0.175	
   Rhinorrhea, n (%)	1117 (43.8)	495 (44.9)	622 (42.9)	0.301	
   Nasal congestion, n (%)	1086 (42.5)	452 (41.0)	634 (43.7)	0.175	
   Wheezing, n (%)	1099 (43.0)	448 (40.7)	651 (44.9)	0.033	
   Acute otitis media, n (%)	553 (21.7)	284 (25.8)	269 (18.5)	< 0.001	
   Seizures, n (%)	202 (7.9)	131 (11.9)	71 (4.9)	< 0.001	
   Poor appetite, n (%)	838 (32.8)	351 (31.9)	487 (33.6)	0.362	
   Diarrhea, n (%)	115 (4.5)	56 (5.1)	59 (4.1)	0.220	
   Vomiting, n (%)	174 (6.8)	72 (6.5)	102 (7.0)	0.622	
Laboratory findings, median (IQR)					
   Oxygen saturation, %	94.0 (91.0, 97.0)	93.0 (90.0, 97.0)	94.0 (91.0, 98.0)	0.104	
   Leukocyte count, ×109/L	12.3 (10.1, 14.9)	13.8 (11.0, 16.7)	11.1 (9.5,13.9)	< 0.001	
   NLR	3.9 (3.1, 5.3)	4.2 (3.5, 6.2)	3.6 (2.8, 5.0)	< 0.001	
   CD4+ /CD8+ T cell ratio	1.2 (0.9, 1.6)	1.2 (0.8, 1.5)	1.2 (1.0, 1.7)	0.621	
   ESR, mm/H	17.0 (15.0, 23.0)	21.0 (14.0, 29.0)	16.0 (14.0, 22.0)	0.195	
   CRP, mg/L	11.7 (8.0, 17.9)	12.3 (8.9, 19.6)	9.8 (4.7, 17.2)	0.009	
   PCT, ng/mL	0.4 (0.1, 1.1)	0.4 (0.1, 1.2)	0.4 (0.2, 1.1)	0.418	
   IL-6, pg/mL	18.2 (10.3, 27.8)	19.5 (12.4, 32.8)	16.5 (10.2, 27.3)	0.007	
   ALT, U/L	25.0 (20.0, 37.0)	24.0 (19.0, 33.0)	25.0 (21.0, 39.0)	0.110	
   AST, U/L	27.0 (20.0, 35.0)	26.0 (19.0, 35.0)	28.0 (22.0, 35.0)	0.322	
   LDH, U/L	390.6 (350.7, 509.0)	398.6 (351.2, 568.9)	387.0 (349.6, 505.8)	0.175	
   Cr, umol/L	29.5 (24.9, 37.8)	31.6 (26.3, 38.2)	29.2 (23.9, 37.6)	0.382	
   Urea, mmol/L	3.2 (2.2, 4.7)	3.0 (2.1, 4.5)	3.2 (2.2, 4.7)	0.510	
   CK-MB, U/L	48.1 (39.3, 55.0)	51.0 (41.4, 60.8)	46.3 (39.0, 53.6)	0.139	
   Co-infection, n (%)	957 (37.5)	439 (39.8)	518 (35.7)	0.032	
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK-MB, creatine kinase myocardial band; Cr, creatinine; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IL-6, interleukin 6; IQR, interquartile ranges; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; PCT, procalcitonin

Table 3 Outcome measures of patients in the pre- and post-COVID-19 groups

Characteristics	Total
(n = 2553)	Post-COVID-19 group (n = 1102)	Pre-COVID-19 group (n = 1451)	P value	
SLRTI, n (%)	483 (18.9)	239 (21.7)	244 (16.8)	0.002	
Mechanical ventilation, n (%)	156 (6.1)	86 (7.8)	70 (4.8)	0.002	
ICU admission, n (%)	210 (8.2)	101 (9.2)	109 (7.5)	0.132	
LOS, days, median (IQR)	5.0 (4.0, 7.0)	6.0 (4.0, 8.0)	5.0 (4.0, 7.0)	< 0.001	
ICU, intensive care unit; IQR, interquartile ranges; LOS, length of hospital stay; SLRTI, severe lower respiratory tract infection

Co-infection of patients

Co-infection was detected in 439 cases (39.8%) in the post-COVID-19 group and 518 cases (35.7%) in the pre-COVID-19 group. As summarized in Table 4, dual infection was the most common mixed infection [299 (68.1%)] in the post-COVID-19 group, followed by triple infection [98 (22.3%)] and quadruple infection [42 (9.6%)]. The three most common combinations of co-infection were RSV + IAV [60 (13.7%)], RSV + M. pneumoniae [47 (10.7%)], and RSV + HRV [38 (8.7%)].

Table 4 Co-infection of patients in the pre- and post-COVID-19 groups

Characteristics	Post-COVID-19 group (n = 439)	Pre-COVID-19 group (n = 518)	P value	
Dual infection, n (%)	299 (68.1)	412 (79.5)	< 0.001	
Triple infection, n (%)	98 (22.3)	80 (15.4)	0.006	
Quadruple infection, n (%)	42 (9.6)	26 (5.0)	0.006	
Main combinations of co-infection, n (%)	
   RSV + IAV	60 (13.7)	35 (6.8)	< 0.001	
   RSV + HRV	38 (8.7)	73 (14.1)	0.009	
   RSV + HPIV	24 (5.5)	61 (11.8)	0.001	
   RSV + HMPV	7 (1.6)	69 (13.3)	< 0.001	
   RSV + M. pneumoniae	47 (10.7)	33 (6.4)	0.016	
HMPV, human metapneumovirus; HPIV, human parainfluenza virus; HRV, human rhinovirus; IAV, influenza A virus; M. pneumoniae, mycoplasma pneumoniae; RSV, respiratory syncytial virus

The concurrent infection in the pre-COVID-19 group was also dominated by dual infection, with a higher proportion than that in the post-COVID-19 group [79.5% (412/518) vs. 68.1% (299/439), P < 0.001]; whereas the proportions of triple and quadruple infections were significantly lower than those in the post-COVID-19 group [15.4% (80/518) vs. 22.3% (98/439), P = 0.006; 5.0% (26/518) vs.9.6% (42/439), P = 0.006)]. The top three combinations of co-infections in the pre-COVID-19 group in order were RSV + HRV [73 (14.1%)], RSV + HMPV [69 (13.3%)], and RSV + HPIV [61 (11.8%)].

Independent risk factors for RSV-associated SLRTI

As shown in Tables 5 and 239 (21.7%) cases in the post-COVID-19 group and 244 (16.8%) cases in the pre-COVID-19 group were classified into respective severe subgroups. Patients’ characteristics of severe and non- severe subgroups in both pre- and post-COVID-19 groups were summarized in Tables 5, 6 and 7. Variables with significant differences between severe and non-severe subgroups were included into logistic regression analysis. Finally, age, low birthweight, preterm birth, personal history of atopy, underlying condition, NLR, and IL-6 were identified as the shared independent risk factors of SLRTI in both pre- and post-COVID-19 groups, whereas seizures and co-infection were independently associated with SLRTI only in the post-COVID-19 group (Fig. 3).

Table 5 General characteristics of patients in the respective severe and non-severe subgroups

Characteristics	Post-COVID-19 group	P value	Pre-COVID-19 group	P value	
Severe (n = 239)	Non-severe (n = 863)	Severe (n = 244)	Non-severe (n = 1207)	
Age, months, median (IQR)	11.2 (9.3, 17.9)	17.3 (14.1, 22.5)	< 0.001	2.2 (1.0, 5.1)	5.8 (2.3, 12.4)	< 0.001	
Male, n (%)	139 (58.2)	489 (56.7)	0.679	151 (61.9)	713 (59.1)	0.422	
Low birthweight, n (%)	48 (20.1)	107 (12.4)	0.002	42 (17.2)	133 (11.0)	0.007	
Preterm birth, n (%)	40 (16.7)	96 (11.1)	0.020	44 (18.0)	156 (13.8)	0.035	
Personal history of atopy, n (%)	69 (28.9)	180 (20.9)	0.009	63 (25.8)	242 (20.0)	0.044	
Family history of atopy, n (%)	45 (18.8)	123 (14.3)	0.082	45 (18.4)	149 (12.3)	0.011	
Non-EBF, n (%)	116 (48.5)	389 (45.1)	0.342	107 (43.9)	545 (45.2)	0.709	
Underlying condition, n (%)	51 (21.3)	112 (13.0)	0.001	46 (18.9)	152 (12.6)	0.009	
Duration of symptoms prior to admission, days, median (IQR)	1.0 (1.0, 2.0)	1.0 (1.0, 1.0)	0.581	1.0 (1.0, 2.0)	1.0 (1.0, 2.0)	0.880	
IQR, interquartile ranges; Non-EBF, non-exclusively breastfeeding

Table 6 Clinical and laboratory characteristics of patients in the respective severe and non-severe subgroups

Characteristics	Post-COVID-19 group	P value	Pre-COVID-19 group	P value	
Severe (n = 239)	Non-severe (n = 863)	Severe (n = 244)	Non-severe (n = 1207)	
Clinical symptoms		
   Fever, n (%)	136 (56.9)	446 (51.7)	0.152	127 (52.0)	575 (47.6)	0.209	
   Fever peak, °C, median (IQR)	38.1 (37.7, 39.2)	37.8 (37.1, 38.3)	0.018	38.4 (37.2, 39.1)	37.6 (37.0, 38.0)	0.008	
   Cough, n (%)	219 (91.6)	774 (89.7)	0.373	212 (86.9)	1071 (88.7)	0.411	
   Rhinorrhea, n (%)	115 (48.1)	380 (44.0)	0.261	115 (47.1)	507 (42.0)	0.140	
   Nasal congestion, n (%)	103 (43.1)	349 (40.4)	0.460	112 (45.9)	522 (43.2)	0.446	
   Wheezing, n (%)	111 (46.4)	337 (39.0)	0.039	127 (52.0)	524 (43.4)	0.013	
   Acute otitis media, n (%)	66 (27.4)	218 (25.3)	0.461	52 (21.3)	217 (18.0)	0.222	
   Seizure, n (%)	41 (17.2)	90 (10.4)	0.004	17 (7.0)	54 (4.5)	0.100	
   Poor appetite, n (%)	79 (33.1)	272 (31.5)	0.652	93 (38.1)	394 (32.6)	0.099	
   Diarrhea, n (%)	11 (4.6)	45 (5.2)	0.703	12 (4.9)	47 (3.9)	0.460	
   Vomiting, n (%)	17 (7.1)	55 (6.4)	0.682	19 (7.8)	83 (6.9)	0.612	
Laboratory findings, median (IQR)		
   Oxygen saturation, %	91.0 (88.0, 95.0)	93.0 (90.0, 98.0)	0.072	93.0 (91.0, 95.0)	94.0 (91.0, 98.0)	0.274	
   Leukocyte count, ×109/L	16.4 (13.2, 19.8)	12.9 (10.7, 15.6)	< 0.001	14.5 (11.3, 17.9)	11.0 (9.2, 13.4)	< 0.001	
   NLR	5.6 (3.9, 8.8)	4.0 (3.3, 5.9)	< 0.001	5.3 (3.3, 7.9)	3.5 (2.7, 4.8)	< 0.001	
   CD4+ /CD8+ T cell ratio	1.1 (0.7, 1.3)	1.2 (1.0, 1.6)	0.063	1.1 (0.7, 1.6)	1.3 (1.0, 1.8)	0.037	
   ESR, mm/H	23.0 (16.0, 33.0)	20.0 (13.0, 27.0)	0.182	20.0 (15.0, 26.0)	16.0 (13.0, 21.0)	0.167	
   CRP, mg/L	16.3 (14.8, 22.5)	11.4 (8.1, 14.3)	< 0.001	15.1 (12.5, 22.7)	9.3 (4.5, 16.7)	< 0.001	
   PCT, ng/mL	0.5 (0.3, 1.6)	0.4 (0.2, 0.9)	0.032	0.5 (0.5, 1.3)	0.4 (0.2, 0.9)	0.076	
   IL-6, pg/mL	22.8 (18.1, 36.7)	17.9 (11.2, 30.5)	0.002	21.7 (17.0, 34.1)	15.5 (9.9, 25.5)	< 0.001	
   ALT, U/L	24.0 (20.0, 41.0)	24.0 (19.0, 32.0)	0.416	28.0 (24.0, 41.0)	24.0 (20.0. 37.0)	0.461	
   AST, U/L	28.0 (20.0, 38.0)	26.0 (19.0, 34.0)	0.337	30.0 (24.0, 38.0)	27.0 (20.0, 33.0)	0.215	
   LDH, U/L	402.7 (369.1, 577.2)	395.8 (346.3, 552.1)	0.146	401.1 (365.5, 521.0)	379.4 (347.5, 491.3)	0.387	
   Cr, umol/L	34.5 (29.3, 41.2)	30.4 (25.7, 36.9)	0.484	34.1(26.2, 39.4)	28.5 (21.6, 35.3)	0.109	
   Urea, mmol/L	3.1 (2.6, 4.8)	3.0 (2.0, 4.4)	0.391	3.5 (3.0, 6.9)	3.0 (2.0, 4.4)	0.175	
   CK-MB, U/L	54.7 (44.1, 69.6)	50.2 (40.5, 58.3)	0.307	51.0 (46.2, 57.8)	45.0 (37.1, 52.3)	0.692	
   Co-infection, n (%)	110 (46.0)	329 (38.1)	0.027	97 (39.8)	421 (34.9)	0.147	
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK-MB, creatine kinase myocardial band; Cr, creatinine; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IL-6, interleukin 6; IQR, interquartile ranges; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; PCT, procalcitonin

Table 7 Outcome measures of patients in the respective severe and non-severe subgroups

Characteristics	Post-COVID-19 group	P value	Pre-COVID-19 group	P value	
Severe (n = 239)	Non-severe (n = 863)	Severe (n = 244)	Non-severe (n = 1207)	
Mechanical ventilation, n (%)	86 (36.0)	0	< 0.001	70 (28.7)	0	< 0.001	
ICU admission, n (%)	101 (42.3)	0	< 0.001	109 (44.7)	0	< 0.001	
LOS, days, median (IQR)	7.0 (6.0, 9.0)	6.0 (4.0, 7.0)	< 0.001	6.0 (5.0, 8.0)	5.0 (4.0, 7.0)	0.002	
ICU, intensive care unit; LOS, length of hospital stay

Fig. 3 The independent risk factors of RSV-related SLRTI in the pre- and post-COVID-19 groups. CI, confidence interval; NLR neutrophil-lymphocyte ratio; OR, odd ratio; RSV, respiratory syncytial virus; SLRTI, severe lower respiratory tract infection

Discussion

Based on multicenter data, this study assessed children hospitalized for RSV infection during the pre- (2018–2019) and post-COVID-19 eras (2023) in Yunnan, China, to clarify the differences in characteristics of pediatric RSV infection between the two periods.

Before the COVID-19 pandemic, the RSV activities generally followed a predictable seasonal pattern with epidemic peaks from October to April of the following year in the Northern Hemisphere [5]. Consistent with this knowledge, in the pre-COVID-19 group of our study, the RSV-associated hospitalizations occurred more frequently during January- April and October- December in both 2018 and 2019. Whereas the post-COVID-19 group showed a pronounced off-season RSV endemic from April to September 2023, suggesting a significant seasonal shift in RSV prevalence during the post-COVID-19 era compared to the pre-COVID-19 era. Similar phenomena were also observed in multiple countries and regions, such as Japan and Italy [18, 19]. In addition, it should be noted, as we mentioned earlier, that RSV activity was barely recorded worldwide during the COVID-19 pandemic due to the strict implementation of COVID-19-related NPIs. Therefore, it may be difficult to determine the actual epidemiological and clinical features of RSV during the pandemic period. This is also the main reason why this study did not collect RSV data from the pandemic period for comparison and analysis.

There was an increase in age of patients in the post-COVID-19 group than those in the pre-COVID-19 group. It was well known that younger children, especially those under one year of age, were the main RSV-susceptible population in the past [20]. In our study, the pre-COVID-19 group showed a median age of 5.5 months, which was quite close to that reported in the previous literature [21, 22]. However, a significantly older median age (15.1 months) was found in the post-COVID − 19 group. Similarly, Australia, one of the earliest countries suffering from the out-of-season RSV outbreak after easing of COVID-19 containment, reported that RSV patients during the post-COVID-19 period had a median age of 16.4 months, which was more than twice that observed before the emergence of COVID-19 pandemic (8.1 months) [12]. Jiang et al. [23] recently demonstrated the immunity debt due to the absent seasonal RSV circulation mainly caused by NPIs. The levels of RSV-specific antibody among children were significantly declined during the COVID-19 pandemic compared to those in the pre-pandemic period, and the changes of antibody levels presented marked variability across different age groups, with a more prominent decrease identified in older children. This might partially explain the trend towards increasing age of children with RSV infection in the post-COVID-19 era.

Besides, more frequent clinical manifestations (fever, acute otitis media, seizures), elevated inflammatory indicators (NLR, CRP, IL-6), higher proportion of SLRTI, increased requirement of mechanical ventilation, and longer LOS were observed in the post-COVID-19 group compared to those in the pre-COVID-19 group, suggesting a greater clinical severity of RSV infection in the post-COVID-19 group. The discrepancy of clinical severity between the two groups was probably linked to two factors: immunity debt caused by NPIs and immune dysregulation associated with prior SARS-CoV-2 infection [24]. First, the absence of RSV seasonal exposure due to the implementation of NPIs during COVID-19 pandemic was confirmed to generate immunity debt [8, 23], which might exacerbate the clinical course of RSV infection. Second, previous studies revealed that compared with healthy individuals, patients who had overcome acute SARS-CoV-2 infection for over two months showed significant impairment of T, NKT, and NKT-like cells [25]. Meanwhile, the absence of naive T and B cells could still be found in some recovered patients at eight months after acute SARS-CoV-2 infection [26]. Altogether, these findings implied that immune dysregulation might persist for months following the recovery from acute SARS-CoV-2 infection, potentially causing harmful effects on the immune system. Given the ultra-high prior infection rate of SARS-CoV-2 in China [27], potential immune dysregulation could be a non-negligible factor affecting RSV severity in the post-COVID-19 era. Of course, we also cannot ignore that the increased severity of symptoms observed in the post-COVID-19 group might also be attributed to an increased likelihood of encountering severe cases, given the intensified RSV circulation and its associated hospitalization burden worldwide. Consistent with this, in our study, the number of inpatients in the post-COVID-19 group (1102 cases) was indeed greater than that in any single year of the pre-COVID-19 group (658 cases in 2018 and 793 cases in 2019). Therefore, although the severity evaluation of RSV was performed based on multiple aspects (inflammatory indicators, proportion of severe case, requirement of mechanical ventilation, LOS) in this study, we must acknowledge the potential that the increase in hospitalized cases could have led to a higher likelihood of observing severe cases. In addition, it was recently proposed that conditions associated with the COVID-19 pandemic perhaps favored the emergence of more virulent or contagious RSV strains [24], but the current findings do not support this perspective [28, 29] and more reliable evidence is required.

In addition, one noteworthy phenomenon was that compared to the pre-COVID-19 group, the post-COVID-19 group showed a significantly increased incidence of seizures (11.9% vs. 4.9%), which might serve as the vital evidence suggesting the association between COVID-19 pandemic and the heightened clinical severity of RSV infection during the post-pandemic period. Combined with previous studies [27, 30–33], the reactivation of residual SARS-CoV-2 virus among the recovered individuals and/or the current co-infection with Omicron variant might partially account for the raised incidence of seizures in pediatric RSV infection. Furthermore, even before the COVID-19 pandemic, RSV infection itself could lead to fatal neurological damage in children [34], so attention to neurological complications is particularly needed in the clinical management of pediatric RSV infection during the post-COVID-19 period. Another significant clinical alteration of RSV infection in the post-COVID-19 era was the decreased proportion of wheezing (44.9% and 40.7% in pre- and post-COVID-19 groups, respectively), which was one of the most common symptoms of children with RSV infection in the past. This change implied that clinicians also should pay sufficient attention to RSV patients without wheezing during the post-COVID-19 era, in order to avoid missed diagnosis and misdiagnosis.

Moreover, in this study, the post-COVID-19 group showed a higher proportion of co-infections (39.8% vs. 35.7%), with more frequent multiple infections (triple infection: 22.3% vs. 15.4%; quadruple infection: 9.6% vs. 5.0%), compared to the pre-COVID-19 group. This phenomenon might also be relevant to the NPIs-induced immunity debt, which affected not only RSV but also other pathogens. Variable degrees of resurgences in multiple pathogens, such as influenza viruses and M. pneumoniae, have been reported after the easing of NPIs [8, 35]. This perhaps represented a potential cause underlying the increased co-infections, especially multiple infections, during the post-COVID-19 era. Simultaneously, increased co-infection might be one of reasons why the RSV infection in the post-COVID-19 group displayed a greater clinical severity than the traditional seasonal RSV infection, because numerous studies have shown that mixed infections tended to be closely linked to more severe clinical outcomes [36]. Furthermore, significant differences in the pathogen spectrum of co-infections were observed between the two groups. In the post-COVID-19 group, the top three combinations of co-infections were RSV + IAV, RSV + M. pneumoniae, and RSV + HRV, while they were RSV + HRV, RSV + HMPV, and RSV + HPIV in the pre-COVID-19 group. Particularly, it is important to mention that incidences of RSV + IAV and RSV + M. pneumoniae in the post-COVID-19 group were significantly higher than those in the pre-COVID-19 group. Haney et al. [37]. have confirmed that the co-infection of RSV and IAV forms hybrid virus particles (HVPs), which can utilize RSV fusion glycoprotein to escape antiviral neutralizing antibodies, thus enhancing viral infection and transmission among cells. This interaction between RSV and IVA might affect virus pathogenesis by expanding virus tropism and enabling immune escape. This experimental finding may well explain the clinical observation that co-infection of RSV/IVA is associated with more severe outcomes [38, 39]. A similar trend was reported in individuals concurrently infected with RSV and M. pneumoniae, where the clinical severity was significantly higher in those with co-infection compared to those with single RSV infection [40]. Therefore, the changes in pathogen spectrum of mixed infections might also be one of the potential factors causing the variation in clinical characteristics and severity of RSV infection between pre- and post-COVID-19 groups.

To better facilitate the understanding and early recognition of RSV-associated SLRTI, we identified and further compared the independent risk factors of SLRTI between the pre- and post-COVID-19 groups. The result showed that age, low birthweight, preterm birth, personal history of atopy, underlying condition, NLR, and IL-6 were independently associated with occurrence of RSV-associated SLRTI in both pre- and post-COVID-19 groups. This was not unexpected, because these factors have been widely reported and recognized as the effective predictors for severe RSV infection in previous research [21, 41, 42]. However, an interesting finding in our study was that in addition to the seven shared risk factors, seizures and co-infection were identified as the risk factors of SLRTI only in the post-COVID-19 group. This again suggested that more frequent seizures and co-infection were likely to be significant characteristics of RSV infection in the post-COVID-19 era and played important roles in the progression of RSV infection, reflecting the potential impact of COVID-19 pandemic on RSV infection. Therefore, strengthening the evaluation of these above indicators, especially seizures and co-infections, are essential for the early recognition of RSV-associated SLRTI in the post-COVID-19 era.

The present study has several limitations that should be considered. First, there were inherent biases due to the retrospective nature of study. Second, only inpatients were included in this study. To better explore epidemic dynamics of RSV, outpatients should be enrolled in future research. Another limitation is that only one year of post-pandemic RSV data was collected and analyzed, so it might not be able to fully reflect the dynamic changes of RSV during this period. In addition, the present study did not classify underlying condition in detail, which resulted in the failure to fully explain the influence of different comorbidities on the occurrence of RSV-associated SLRTI, despite identifying underlying condition as an independent risk factor. Finally, we did not analyze the circulating RSV strains at the genomic level to assess possible discrepancy between the pre- and post-COVID-19 periods.

Conclusions

This multicenter retrospective study indicated an out-of-season RSV endemic in Yunnan, China, during the post-COVID-19 era, with a peak period of pediatric RSV hospitalization from April to September 2023. Children hospitalized for RSV infection in the post-pandemic era showed a trend towards older age, different clinical features, and increased severity. Meanwhile, in addition to seven shared risk factors (age, low birthweight, preterm birth, personal history of atopy, underlying condition, NLR, IL-6) for RSV-associated SLRTI in both pre- and post-COVID-19 groups, seizures and co-infection were independently associated with SLRTI among patients only in the post-COVID-19 group. It is essential for clinicians to be aware of these changes and differences between the two periods, in order to optimize the clinical management of such patients and reduce the occurrence of RSV-related SLRTI and deaths.

Acknowledgements

Not applicable.

Author contributions

L.H.F. contributed to conceptualization, formal analysis, funding acquisition, and writing–original draft. W.Y.Y., Z.X.Z., and L.H.Y. were involved in methodology, formal analysis, and supervision. X.M., L.R., L.C.Y., L.W., F.Q.L., G.Y.J., and H.R.W. performed data extraction and visualization. F.H.M. contributed to conceptualization, methodology, project administration, funding acquisition, supervision, writing–review and editing. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (grant numbers: 81960021 and 82360025) and the Yunnan Provincial Department of Education Science Research Fund Project (grant number: 2023Y0790).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committees of Kunming Children’s Hospital Affiliated to Kunming Medical University (the lead institution of this study) (2023-05-012-K01), who also waived the informed consent due to the retrospective design of the study.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Abbreviations

ALT Alanine transaminase

AST Aspartate transaminase

CK MB-Creatine kinase-MB

Cr Creatinine

CRP C-reactive protein

EBF Exclusively breastfeeding

ESR Erythrocyte sedimentation rate

HAdV Human adenovirus

HMPV Human metapneumovirus

HPIV Human parainfluenza virus

HRV Human rhinovirus

HVPs Hybrid virus particles

IAV Influenza A virus

IBV Influenza B virus

ICU Intensive care unit

IL 6-Interleukin 6

IQR Interquartile range

LDH Lactate dehydrogenase

LOS Length of hospital stay

M. pneumoniae Mycoplasma pneumoniae

NLR Neutrophil-to-lymphocyte ratio

NPIs Non-pharmaceutical interventions

PCT Procalcitonin

RSV Respiratory syncytial virus

SLRTI Severe lower respiratory tract infection

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. O’Brien KL Baggett HC Brooks WA Feikin DR Hammitt LL Higdon MM Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study Lancet 2019 394 10200 757 79 10.1016/S0140-6736(19)30721-4 31257127
O’Brien KL, Baggett HC, Brooks WA, Feikin DR, Hammitt LL, Higdon MM, et al. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019;394(10200):757–79.31257127
2. Li Y Wang X Blau DM Caballero MT Feikin DR Gill CJ Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis Lancet 2022 399 10340 2047 64 10.1016/S0140-6736(22)00478-0 35598608
Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–64.35598608
3. Cevigney R, Leary C, Gonik B. Adjustable algorithmic tool for assessing the effectiveness of maternal respiratory syncytial virus (RSV) vaccination on infant mortality in developing countries. Infect Dis Obstet Gynecol. 2021, 2021:5536633.
4. Laudanno SL Sánchez Yanotti CI Polack FP RSV lower respiratory tract illness in infants of low- and middle-income countries Acta Med Acad 2020 49 2 191 7 10.5644/ama2006-124.297 33189124
Laudanno SL, Sánchez Yanotti CI, Polack FP. RSV lower respiratory tract illness in infants of low- and middle-income countries. Acta Med Acad. 2020;49(2):191–7.33189124
5. Li Y Reeves RM Wang X Bassat Q Brooks WA Cohen C Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis Lancet Glob Health 2019 7 8 e1031 45 10.1016/S2214-109X(19)30264-5 31303294
Li Y, Reeves RM, Wang X, Bassat Q, Brooks WA, Cohen C, et al. Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet Glob Health. 2019;7(8):e1031–45.31303294
6. Oh KB Doherty TM Vetter V Bonanni P Lifting non-pharmaceutical interventions following the COVID-19 pandemic - the quiet before the storm? Expert Rev Vaccines 2022 21 11 1541 53 10.1080/14760584.2022.2117693 36039786
Oh KB, Doherty TM, Vetter V, Bonanni P. Lifting non-pharmaceutical interventions following the COVID-19 pandemic - the quiet before the storm? Expert Rev Vaccines. 2022;21(11):1541–53.36039786
7. Treggiari D Pomari C Zavarise G Piubelli C Formenti F Perandin F Characteristics of respiratory syncytial virus infections in children in the post-COVID Seasons: A Northern Italy hospital experience Viruses 2024 16 1 126 10.3390/v16010126 38257826
Treggiari D, Pomari C, Zavarise G, Piubelli C, Formenti F, Perandin F. Characteristics of respiratory syncytial virus infections in children in the post-COVID Seasons: A Northern Italy hospital experience. Viruses. 2024;16(1):126.38257826
8. Cohen R Pettoello-Mantovani M Somekh E Levy C European pediatric societies call for an implementation of regular vaccination programs to contrast the immunity debt associated to coronavirus disease-2019 pandemic in children J Pediatr 2022 242 260 e261263 10.1016/j.jpeds.2021.11.061 34848191
Cohen R, Pettoello-Mantovani M, Somekh E, Levy C. European pediatric societies call for an implementation of regular vaccination programs to contrast the immunity debt associated to coronavirus disease-2019 pandemic in children. J Pediatr. 2022;242:260–e261263.34848191
9. Piedra PA Jewell AM Cron SG Atmar RL Glezen WP Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies Vaccine 2003 21 24 3479 82 10.1016/S0264-410X(03)00355-4 12850364
Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine. 2003;21(24):3479–82.12850364
10. Steff AM Monroe J Friedrich K Chandramouli S Nguyen TL Tian S Pre-fusion RSV F strongly boosts pre-fusion specific neutralizing responses in cattle pre-exposed to bovine RSV Nat Commun 2017 8 1 1085 10.1038/s41467-017-01092-4 29057917
Steff AM, Monroe J, Friedrich K, Chandramouli S, Nguyen TL, Tian S, et al. Pre-fusion RSV F strongly boosts pre-fusion specific neutralizing responses in cattle pre-exposed to bovine RSV. Nat Commun. 2017;8(1):1085.29057917
11. Zhu L Luo T Yuan Y Yang S Niu C Gong T Epidemiological characteristics of respiratory viruses in hospitalized children during the COVID-19 pandemic in southwestern China Front Cell Infect Microbiol 2023 13 1142199 10.3389/fcimb.2023.1142199 37153160
Zhu L, Luo T, Yuan Y, Yang S, Niu C, Gong T, et al. Epidemiological characteristics of respiratory viruses in hospitalized children during the COVID-19 pandemic in southwestern China. Front Cell Infect Microbiol. 2023;13:1142199.37153160
12. Foley DA Phuong LK Peplinski J Lim SM Lee WH Farhat A Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia Arch Dis Child 2022 107 3 e7 10.1136/archdischild-2021-322507 34433552
Foley DA, Phuong LK, Peplinski J, Lim SM, Lee WH, Farhat A, et al. Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia. Arch Dis Child. 2022;107(3):e7.34433552
13. Hatter L Eathorne A Hills T Bruce P Beasley R Respiratory syncytial virus: paying the immunity debt with interest Lancet Child Adolesc Health 2021 5 12 e44 5 10.1016/S2352-4642(21)00333-3 34695374
Hatter L, Eathorne A, Hills T, Bruce P, Beasley R. Respiratory syncytial virus: paying the immunity debt with interest. Lancet Child Adolesc Health. 2021;5(12):e44–5.34695374
14. Ujiie M Tsuzuki S Nakamoto T Iwamoto N Resurgence of respiratory syncytial virus infections during COVID-19 pandemic, Tokyo, Japan Emerg Infect Dis 2021 27 11 2969 70 10.3201/eid2711.211565 34388086
Ujiie M, Tsuzuki S, Nakamoto T, Iwamoto N. Resurgence of respiratory syncytial virus infections during COVID-19 pandemic, Tokyo, Japan. Emerg Infect Dis. 2021;27(11):2969–70.34388086
15. Perk Y Özdil M Respiratory syncytial virüs infections in neonates and infants Turk Pediatri Ars 2018 53 2 63 70 10.5152/TurkPediatriArs.2018.6939 30116126
Perk Y, Özdil M. Respiratory syncytial virüs infections in neonates and infants. Turk Pediatri Ars. 2018;53(2):63–70.30116126
16. Rodrigues CMC Groves H Community-Acquired Pneumonia in children: the challenges of microbiological diagnosis J Clin Microbiol 2018 56 3 e01318 17 10.1128/JCM.01318-17 29237789
Rodrigues CMC, Groves H. Community-Acquired Pneumonia in children: the challenges of microbiological diagnosis. J Clin Microbiol. 2018;56(3):e01318–17.29237789
17. Brent B Obonyo N Akech S Shebbe M Mpoya A Mturi N Assessment of myocardial function in Kenyan children with severe, acute malnutrition: the cardiac physiology in malnutrition (CAPMAL) study JAMA Netw Open 2019 2 3 e191054 10.1001/jamanetworkopen.2019.1054 30901050
Brent B, Obonyo N, Akech S, Shebbe M, Mpoya A, Mturi N, et al. Assessment of myocardial function in Kenyan children with severe, acute malnutrition: the cardiac physiology in malnutrition (CAPMAL) study. JAMA Netw Open. 2019;2(3):e191054.30901050
18. McNab S Ha Do LA Clifford V Crawford NW Daley A Mulholland K Changing epidemiology of respiratory syncytial virus in Australia-delayed re-emergence in Victoria compared to Western Australia/New South Wales (WA/NSW) after prolonged lock-down for coronavirus disease 2019 (COVID-19) Clin Infect Dis 2021 73 12 2365 6 10.1093/cid/ciab240 33735388
McNab S, Ha Do LA, Clifford V, Crawford NW, Daley A, Mulholland K, et al. Changing epidemiology of respiratory syncytial virus in Australia-delayed re-emergence in Victoria compared to Western Australia/New South Wales (WA/NSW) after prolonged lock-down for coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2021;73(12):2365–6.33735388
19. Ozeki S Kawada JI Yamashita D Yasufuku C Akano T Kato M Impact of the coronavirus disease 2019 pandemic on the clinical features of pediatric respiratory syncytial virus infection in Japan Open Forum Infect Dis 2022 9 11 ofac562 10.1093/ofid/ofac562 36381619
Ozeki S, Kawada JI, Yamashita D, Yasufuku C, Akano T, Kato M, et al. Impact of the coronavirus disease 2019 pandemic on the clinical features of pediatric respiratory syncytial virus infection in Japan. Open Forum Infect Dis. 2022;9(11):ofac562.36381619
20. Faraguna MC Lepri I Clavenna A Bonati M Vimercati C Sala D The bronchiolitis epidemic in 2021–2022 during the SARS-CoV-2 pandemic: experience of a third level centre in Northern Italy Ital J Pediatr 2023 49 1 26 10.1186/s13052-023-01425-8 36803828
Faraguna MC, Lepri I, Clavenna A, Bonati M, Vimercati C, Sala D, et al. The bronchiolitis epidemic in 2021–2022 during the SARS-CoV-2 pandemic: experience of a third level centre in Northern Italy. Ital J Pediatr. 2023;49(1):26.36803828
21. Anderson J Oeum M Verkolf E Licciardi PV Mulholland K Nguyen C Factors associated with severe respiratory syncytial virus disease in hospitalised children: a retrospective analysis Arch Dis Child 2022 107 4 359 64 10.1136/archdischild-2021-322435 34526293
Anderson J, Oeum M, Verkolf E, Licciardi PV, Mulholland K, Nguyen C, et al. Factors associated with severe respiratory syncytial virus disease in hospitalised children: a retrospective analysis. Arch Dis Child. 2022;107(4):359–64.34526293
22. Hassan MZ Islam MA Haider S Shirin T Chowdhury F Respiratory syncytial virus-associated deaths among children under five before and during the COVID-19 pandemic in Bangladesh Viruses 2024 16 1 111 10.3390/v16010111 38257812
Hassan MZ, Islam MA, Haider S, Shirin T, Chowdhury F. Respiratory syncytial virus-associated deaths among children under five before and during the COVID-19 pandemic in Bangladesh. Viruses. 2024;16(1):111.38257812
23. Jiang W Xu L Wang Y Hao C Exploring immunity debt: dynamic alterations in RSV antibody levels in children under 5 years during the COVID-19 pandemic J Infect 2024 88 1 53 6 10.1016/j.jinf.2023.10.019 38009717
Jiang W, Xu L, Wang Y, Hao C. Exploring immunity debt: dynamic alterations in RSV antibody levels in children under 5 years during the COVID-19 pandemic. J Infect. 2024;88(1):53–6.38009717
24. Abu-Raya B Viñeta Paramo M Reicherz F Lavoie P Why has the epidemiology of RSV changed during the COVID-19 pandemic? EClinicalMedicine 2023 61 102089 10.1016/j.eclinm.2023.102089 37483545
Abu-Raya B, Viñeta Paramo M, Reicherz F, Lavoie P. Why has the epidemiology of RSV changed during the COVID-19 pandemic? EClinicalMedicine. 2023;61:102089.37483545
25. Liu J Yang X Wang H Li Z Deng H Liu J Analysis of the long-term impact on cellular immunity in COVID-19-Recovered individuals reveals a profound NKT cell impairment mBio 2021 12 2 e00085 21 10.1128/mBio.00085-21 33906918
Liu J, Yang X, Wang H, Li Z, Deng H, Liu J, et al. Analysis of the long-term impact on cellular immunity in COVID-19-Recovered individuals reveals a profound NKT cell impairment. mBio. 2021;12(2):e00085–21.33906918
26. Phetsouphanh C Darley DR Wilson DB Howe A Munier CML Patel SK Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection Nat Immunol 2022 23 2 210 6 10.1038/s41590-021-01113-x 35027728
Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210–6.35027728
27. Fu D He G Li H Tan H Ji X Lin Z Effectiveness of COVID-19 vaccination against SARS-CoV-2 Omicron variant infection and symptoms - China, December 2022-February 2023 China CDC Wkly 2023 5 17 369 73 10.46234/ccdcw2023.070 37197449
Fu D, He G, Li H, Tan H, Ji X, Lin Z, et al. Effectiveness of COVID-19 vaccination against SARS-CoV-2 Omicron variant infection and symptoms - China, December 2022-February 2023. China CDC Wkly. 2023;5(17):369–73.37197449
28. Goya S Sereewit J Pfalmer D Nguyen TV Bakhash S Sobolik EB Genomic characterization of respiratory syncytial virus during 2022-23 outbreak, Washington, USA Emerg Infect Dis 2023 29 4 865 8 10.3201/eid2904.221834 36878012
Goya S, Sereewit J, Pfalmer D, Nguyen TV, Bakhash S, Sobolik EB, et al. Genomic characterization of respiratory syncytial virus during 2022-23 outbreak, Washington, USA. Emerg Infect Dis. 2023;29(4):865–8.36878012
29. Adams G Moreno GK Petros BA Uddin R Levine Z Kotzen B Viral lineages in the 2022 RSV surge in the United States N Engl J Med 2023 388 14 1335 7 10.1056/NEJMc2216153 36812457
Adams G, Moreno GK, Petros BA, Uddin R, Levine Z, Kotzen B, et al. Viral lineages in the 2022 RSV surge in the United States. N Engl J Med. 2023;388(14):1335–7.36812457
30. Liu HF Lu R Yang J Xiang M Ban D Yang JW Evaluation of febrile seizures in children infected with SARS-CoV-2 Omicron variant in Yunnan, China: a multi-center, retrospective observational study Front Pediatr 2023 11 1223521 10.3389/fped.2023.1223521 38027295
Liu HF, Lu R, Yang J, Xiang M, Ban D, Yang JW, et al. Evaluation of febrile seizures in children infected with SARS-CoV-2 Omicron variant in Yunnan, China: a multi-center, retrospective observational study. Front Pediatr. 2023;11:1223521.38027295
31. Callaway E COVID’s future: mini-waves rather than seasonal surges Nature 2023 617 7960 229 30 10.1038/d41586-023-01437-8 37127700
Callaway E. COVID’s future: mini-waves rather than seasonal surges. Nature. 2023;617(7960):229–30.37127700
32. Davis HE McCorkell L Vogel JM Topol EJ Long COVID: major findings, mechanisms and recommendations Nat Rev Microbiol 2023 21 3 133 46 10.1038/s41579-022-00846-2 36639608
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–46.36639608
33. Stein SR Ramelli SC Grazioli A Chung JY Singh M Yinda CK SARS-CoV-2 infection and persistence in the human body and brain at autopsy Nature 2022 612 7941 758 63 10.1038/s41586-022-05542-y 36517603
Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612(7941):758–63.36517603
34. Xu L Gao H Zeng J Liu J Lu C Guan X A fatal case associated with respiratory syncytial virus infection in a young child BMC Infect Dis 2018 18 1 217 10.1186/s12879-018-3123-8 29751747
Xu L, Gao H, Zeng J, Liu J, Lu C, Guan X, et al. A fatal case associated with respiratory syncytial virus infection in a young child. BMC Infect Dis. 2018;18(1):217.29751747
35. Leung C Konya L Su L Postpandemic immunity debt of influenza in the USA and England: an interrupted time series study Public Health 2024 227 239 42 10.1016/j.puhe.2023.12.009 38246119
Leung C, Konya L, Su L. Postpandemic immunity debt of influenza in the USA and England: an interrupted time series study. Public Health. 2024;227:239–42.38246119
36. Li Y Pillai P Miyake F Nair H The role of viral co-infections in the severity of acute respiratory infections among children infected with respiratory syncytial virus (RSV): a systematic review and meta-analysis J Glob Health 2020 10 1 010426 10.7189/jogh.10.010426 32566164
Li Y, Pillai P, Miyake F, Nair H. The role of viral co-infections in the severity of acute respiratory infections among children infected with respiratory syncytial virus (RSV): a systematic review and meta-analysis. J Glob Health. 2020;10(1):010426.32566164
37. Haney J Vijayakrishnan S Streetley J Dee K Goldfarb DM Clarke M Coinfection by influenza a virus and respiratory syncytial virus produces hybrid virus particles Nat Microbiol 2022 7 11 1879 90 10.1038/s41564-022-01242-5 36280786
Haney J, Vijayakrishnan S, Streetley J, Dee K, Goldfarb DM, Clarke M, et al. Coinfection by influenza a virus and respiratory syncytial virus produces hybrid virus particles. Nat Microbiol. 2022;7(11):1879–90.36280786
38. Meskill SD Revell PA Chandramohan L Cruz AT Prevalence of co-infection between respiratory syncytial virus and influenza in children Am J Emerg Med 2017 35 3 495 8 10.1016/j.ajem.2016.12.001 28012809
Meskill SD, Revell PA, Chandramohan L, Cruz AT. Prevalence of co-infection between respiratory syncytial virus and influenza in children. Am J Emerg Med. 2017;35(3):495–8.28012809
39. Zhang Y Zhao J Zou X Fan Y Xiong Z Li B Severity of influenza virus and respiratory syncytial virus coinfections in hospitalized adult patients J Clin Virol 2020 133 104685 10.1016/j.jcv.2020.104685 33220548
Zhang Y, Zhao J, Zou X, Fan Y, Xiong Z, Li B, et al. Severity of influenza virus and respiratory syncytial virus coinfections in hospitalized adult patients. J Clin Virol. 2020;133:104685.33220548
40. Wu SH Chen XQ Kong X Yin PL Dong L Liao PY Characteristics of respiratory syncytial virus-induced bronchiolitis co-infection with Mycoplasma pneumoniae and add-on therapy with montelukast World J Pediatr 2016 12 1 88 95 10.1007/s12519-015-0024-4 25846070
Wu SH, Chen XQ, Kong X, Yin PL, Dong L, Liao PY, et al. Characteristics of respiratory syncytial virus-induced bronchiolitis co-infection with Mycoplasma pneumoniae and add-on therapy with montelukast. World J Pediatr. 2016;12(1):88–95.25846070
41. Kaler J Hussain A Patel K Hernandez T Ray S Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation Cureus 2023 15 3 e36342 37082497
Kaler J, Hussain A, Patel K, Hernandez T, Ray S. Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation. Cureus. 2023;15(3):e36342.37082497
42. Shi T Balsells E Wastnedge E Singleton R Rasmussen ZA Zar HJ Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis J Glob Health 2015 5 2 020416 10.7189/jogh.05.020416 26682048
Shi T, Balsells E, Wastnedge E, Singleton R, Rasmussen ZA, Zar HJ, et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis. J Glob Health. 2015;5(2):020416.26682048
